Home › Companies › Trevi Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Trevi Therapeutics, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 3, 2026: 5 items on Trevi Therapeutics, Inc.’s Form 8-K, filed June 4, 2026: 4 approved · 1 passed (calculated).
Notable dissent: 1 other board item (18.6% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Trevi Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Trevi Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Proposal 1 | 81,567,765 | -- | -- | 18,635,726 | 14,140,404 | 81% | Passed (calculated) | — |
| 2. Appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 | 114,001,970 | 223,323 | 118,602 | -- | -- | 99.8% | Approved | — |
| 3. Compensation of the Company's named executive officers | 98,119,461 | 1,982,126 | 101,904 | -- | 14,140,404 | 98% | Approved | — |
| 4. A&R 2019 Plan | 98,140,470 | 1,961,030 | 101,991 | -- | 14,140,404 | 98% | Approved | — |
| 5. Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares | 110,453,620 | 3,872,599 | 17,676 | -- | -- | 97% | Approved | — |
Source: Trevi Therapeutics, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
197 asset managers disclosed a vote on at least one Trevi Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Trevi Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
84% of fund votes cast · no official result
Description as filed by funds: Election of one Class I director to our Board of Directors, to serve until the 2029 Annual Meeting of Stockholders: Michael Heffernan
The 55 asset managers below reported 22,289,085 for, 4,222,117 withheld, 36 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,723,168 | 0 | 0 | 0 | For |
| Vanguard | 5,885,667 | 0 | 36 | 0 | For |
| MUTUAL FUND SERIES TRUST | 2,622,306 | 0 | 0 | 23,970 | For |
| BlackRock | 2,093,710 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 1,503,499 | Withhold |
| Charles Schwab | 840,997 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 804,021 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 756,714 | Withhold |
| Hartford | 0 | 0 | 0 | 233,747 | Withhold |
| Equitable | 152,842 | 0 | 0 | 80,440 | Mixed |
| Allspring | 0 | 0 | 0 | 222,155 | Withhold |
| OPTIMUM FUND TRUST | 170,067 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,121 | 0 | 0 | 0 | For |
| State Street | 185 | 0 | 0 | 125,042 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 108,812 | Withhold |
| Empower | 89,530 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 0 | 78,615 | Withhold |
| TIAA | 70,732 | 0 | 0 | 0 | For |
| Invesco | 69,371 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 65,412 | 0 | 0 | 0 | For |
| AMG Funds I | 53,566 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 49,804 | Withhold |
| Goldman Sachs | 28,890 | 0 | 0 | 20,610 | Mixed |
| MASTER INVESTMENT PORTFOLIO | 48,119 | 0 | 0 | 0 | For |
| Global X | 44,565 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 200,000,000 SHARES TO 400,000,000 SHARES.
Trevi Therapeutics, Inc.’s own tally for this item (“5. Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares”): 110,453,620 for, 3,872,599 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares was approved.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 25,214,882 for, 1,296,356 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,723,168 | 0 | 0 | 0 | For |
| Vanguard | 5,877,013 | 8,690 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 2,646,276 | 0 | 0 | 0 | For |
| BlackRock | 2,093,710 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,503,499 | 0 | 0 | 0 | For |
| Charles Schwab | 840,997 | 0 | 0 | 0 | For |
| Principal | 352,376 | 451,645 | 0 | 0 | Mixed |
| RBB FUND, INC. | 0 | 756,714 | 0 | 0 | Against |
| Hartford | 233,747 | 0 | 0 | 0 | For |
| Equitable | 233,282 | 0 | 0 | 0 | For |
| Allspring | 222,155 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 170,067 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,121 | 0 | 0 | 0 | For |
| State Street | 125,141 | 86 | 0 | 0 | For |
| Lincoln Financial | 108,812 | 0 | 0 | 0 | For |
| Empower | 89,530 | 0 | 0 | 0 | For |
| AuguStar | 0 | 78,615 | 0 | 0 | Against |
| TIAA | 70,732 | 0 | 0 | 0 | For |
| Invesco | 69,371 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 65,412 | 0 | 0 | 0 | For |
| AMG Funds I | 53,566 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 49,804 | 0 | 0 | 0 | For |
| Goldman Sachs | 49,500 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 48,119 | 0 | 0 | 0 | For |
| Global X | 44,565 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).
98% Approved · of votes cast
Description as filed by funds: APPROVAL OF THE TREVI THERAPEUTICS, INC. AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN.
Trevi Therapeutics, Inc.’s own tally for this item (“4. A&R 2019 Plan”): 98,140,470 for, 1,961,030 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The A&R 2019 Plan was approved.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,723,168 | 0 | 0 | 0 | For |
| Vanguard | 5,885,699 | 4 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 2,646,276 | 0 | 0 | 0 | For |
| BlackRock | 2,093,710 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,503,499 | 0 | 0 | 0 | For |
| Charles Schwab | 840,997 | 0 | 0 | 0 | For |
| Principal | 804,021 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 756,714 | 0 | 0 | 0 | For |
| Hartford | 233,747 | 0 | 0 | 0 | For |
| Equitable | 233,282 | 0 | 0 | 0 | For |
| Allspring | 222,155 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 170,067 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,121 | 0 | 0 | 0 | For |
| State Street | 125,206 | 21 | 0 | 0 | For |
| Lincoln Financial | 108,812 | 0 | 0 | 0 | For |
| Empower | 89,530 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 78,615 | 0 | Abstain |
| TIAA | 70,732 | 0 | 0 | 0 | For |
| Invesco | 69,371 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 65,412 | 0 | 0 | 0 | For |
| AMG Funds I | 53,566 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 49,804 | 0 | 0 | 0 | For |
| Goldman Sachs | 49,500 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 48,119 | 0 | 0 | 0 | For |
| Global X | 44,565 | 0 | 0 | 0 | For |
Fund voting reports, all 53 managers: 26,418,337 for, 25 against, 78,615 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 13,225,026 | 0 | 0 | 0 | For |
| Vident Advisory, LLC | 2,298 | 0 | 0 | 0 | For |
| Keel Point, LLC | 1,082 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 13,228,406 for.
Combines 5 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.
Trevi Therapeutics, Inc.’s own tally for this item (“3. Compensation of the Company's named executive officers”): 98,119,461 for, 1,982,126 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers was approved, on an advisory basis.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,723,168 | 0 | 0 | 0 | For |
| Vanguard | 5,885,699 | 4 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 2,646,276 | 0 | 0 | 0 | For |
| BlackRock | 2,093,710 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,503,499 | 0 | 0 | 0 | For |
| Charles Schwab | 840,997 | 0 | 0 | 0 | For |
| Principal | 804,021 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 756,714 | 0 | 0 | 0 | For |
| Hartford | 233,747 | 0 | 0 | 0 | For |
| Equitable | 233,282 | 0 | 0 | 0 | For |
| Allspring | 222,155 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 170,067 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,121 | 0 | 0 | 0 | For |
| State Street | 125,201 | 26 | 0 | 0 | For |
| Lincoln Financial | 108,812 | 0 | 0 | 0 | For |
| Empower | 89,530 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 78,615 | 0 | Abstain |
| TIAA | 70,732 | 0 | 0 | 0 | For |
| Invesco | 0 | 69,371 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 65,412 | 0 | 0 | 0 | For |
| AMG Funds I | 53,566 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 49,804 | 0 | 0 | 0 | For |
| Goldman Sachs | 49,500 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 48,119 | 0 | 0 | 0 | For |
| Global X | 44,565 | 0 | 0 | 0 | For |
Fund voting reports, all 54 managers: 26,362,141 for, 69,401 against, 78,615 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 13,225,026 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 9,939,547 | 0 | 0 | 0 | For |
| Fidelity | 8,053,640 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 5,094,668 | 0 | 0 | 0 | For |
| BlackRock | 3,278,721 | 25,528 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 3,198,644 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 2,930,957 | 0 | 0 | 0 | For |
| Wellington | 2,772,637 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,675,847 | 0 | 0 | 0 | For |
| AllianceBernstein | 2,635,253 | 0 | 0 | 0 | For |
| Artia Global Partners LP | 2,013,602 | 0 | 0 | 0 | For |
| State Street | 1,770,451 | 17,508 | 0 | 0 | For |
| Siren, L.L.C. | 1,786,867 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,530,435 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 1,485,000 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 1,403,717 | 0 | 0 | 0 | For |
| Rubric Capital Management LP | 1,288,918 | 0 | 0 | 0 | For |
| NAN FUNG TRINITY (HK) Ltd | 1,142,950 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,113,973 | 0 | 0 | 0 | For |
| Logos Global Management LP | 966,371 | 0 | 0 | 0 | For |
| EMERALD ADVISERS, LLC | 873,193 | 0 | 0 | 0 | For |
| Charles Schwab | 863,324 | 0 | 0 | 0 | For |
| Vanguard | 851,928 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 773,620 | 0 | 0 | Against |
| Putnam | 728,406 | 0 | 0 | 0 | For |
Institutional-manager reports, all 160 managers: 78,684,646 for, 1,395,507 against, 69 abstained, 3,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Trevi Therapeutics, Inc.’s own tally for this item (“2. Appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026”): 114,001,970 for, 223,323 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 26,432,603 for, 21 against, 78,615 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,723,168 | 0 | 0 | 0 | For |
| Vanguard | 5,885,703 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 2,646,276 | 0 | 0 | 0 | For |
| BlackRock | 2,093,710 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,503,499 | 0 | 0 | 0 | For |
| Charles Schwab | 840,997 | 0 | 0 | 0 | For |
| Principal | 804,021 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 756,714 | 0 | 0 | 0 | For |
| Hartford | 233,747 | 0 | 0 | 0 | For |
| Equitable | 233,282 | 0 | 0 | 0 | For |
| Allspring | 222,155 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 170,067 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,121 | 0 | 0 | 0 | For |
| State Street | 125,206 | 21 | 0 | 0 | For |
| Lincoln Financial | 108,812 | 0 | 0 | 0 | For |
| Empower | 89,530 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 78,615 | 0 | Abstain |
| TIAA | 70,732 | 0 | 0 | 0 | For |
| Invesco | 69,371 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 65,412 | 0 | 0 | 0 | For |
| AMG Funds I | 53,566 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 49,804 | 0 | 0 | 0 | For |
| Goldman Sachs | 49,500 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 48,119 | 0 | 0 | 0 | For |
| Global X | 44,565 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 128,411,048 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 7.57% |
| 2 | Vanguard | 4.58% |
| 3 | MUTUAL FUND SERIES TRUST | 2.06% |
| 4 | BlackRock | 1.63% |
| 5 | AllianceBernstein | 1.17% |
| 6 | Charles Schwab | 0.65% |
| 7 | Principal | 0.63% |
| 8 | RBB FUND, INC. | 0.59% |
| 9 | Hartford | 0.18% |
| 10 | Equitable | 0.18% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | NEA Management Company, LLC | 10.30% |
| 2 | Frazier Life Sciences Management, L.P. | 7.74% |
| 3 | Fidelity | 6.27% |
| 4 | Vivo Capital, LLC | 3.97% |
| 5 | BlackRock | 2.57% |
| 6 | VIKING GLOBAL INVESTORS LP | 2.49% |
| 7 | MPM BioImpact LLC | 2.28% |
| 8 | Wellington | 2.16% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.08% |
| 10 | AllianceBernstein | 2.05% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Edward Mathers | 15,256,974 | 11.88% | Proxy statement (DEF 14A), table as of April 6, 2026 |
| Entities affiliated with New Enterprise Associates | 15,074,080 | 11.74% | Proxy statement (DEF 14A), table as of April 6, 2026 |
| New Enterprise Associates 16, L.P. | 15,074,080 | 11.74% | Schedule 13D, filed May 7, 2026 |
| Entities affiliated with Frazier Life Sciences | 13,132,880 | 10.23% | Proxy statement (DEF 14A), table as of April 6, 2026 |
| BlackRock | 10,240,186 | 7.97% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 8,038,061 | 6.26% | Form 13F, quarter ended March 31, 2026 |
| Entities affiliated with BlackRock, Inc. | 6,804,338 | 5.30% | Proxy statement (DEF 14A), table as of April 6, 2026 |
| Entities affiliated with FMR LLC | 6,500,009 | 5.06% | Proxy statement (DEF 14A), table as of April 6, 2026 |
| Vanguard Group | 6,434,655 | 5.01% | Form 13F, quarter ended March 31, 2026 |
| Wellington Management | 5,189,088 | 4.04% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 128,411,048 shares outstanding, as reported by Trevi Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Trevi Therapeutics, Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 197 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,090 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — Trevi Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Trevi Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Trevi Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Trevi Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Trevi Therapeutics (TRVI) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/trevi-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.